阅读说明：本技术 一种用于肺结核咯血的缓释栓塞微球 (Slow-release embolism microsphere for pulmonary tuberculosis hemoptysis ) 是由 赵一麟 周媛媛 刘凤武 于 2019-11-13 设计创作，主要内容包括：本发明公开了一种用于肺结核咯血的缓释栓塞微球,其粒径为10-1000μm,其材质为可降解或不可降解的有机材料,其内负载有抗结核杆菌的抗生素或其衍生物。本发明在栓塞止血的可同时缓慢释放抗结核药物,作用于病灶,以缓解和抑制病灶肺部结构的改变,有效避免咯血的复发。本发明中的抗结核药物的缓释能够极大地提高病灶部位药物浓度,相对降低药物在循环系统中的浓度,减少药物的副作用。本发明中药物与微球的组合,方便医师操作同时也给患者带来便利。(The invention discloses a sustained-release embolism microsphere for pulmonary tuberculosis hemoptysis, which has the particle size of 10-1000 mu m, is made of degradable or non-degradable organic materials, and is loaded with antibiotic or derivatives thereof for resisting tubercle bacillus. The invention can slowly release antituberculosis drugs while stopping bleeding by embolism, and acts on focus to relieve and inhibit the change of focus lung structure, thereby effectively avoiding the recurrence of hemoptysis. The slow release of the antituberculosis drug can greatly improve the drug concentration of the focus part, relatively reduce the concentration of the drug in the circulatory system and reduce the side effect of the drug. The combination of the medicine and the microspheres in the invention is convenient for doctors to operate and brings convenience to patients.)

1. A sustained-release embolism microsphere for pulmonary tuberculosis hemoptysis is characterized in that: the material is degradable or non-degradable organic material, and antibiotic or its derivative for resisting tubercle bacillus is loaded in the material, wherein

The organic material is chitin, chitosan, carboxymethyl chitosan, sodium alginate, gelatin, collagen, hyaluronic acid, polypeptide, silk fibroin, carboxymethyl starch, starch acetate, polycaprolactone, polylactic acid, polyglycolic acid, polylactic acid-polyglycolic acid copolymer, polycaprolactone triol, polycaprolactone diol, poly (ethylene glycol) -block-poly (epsilon-caprolactone) methyl ether, polyvinyl alcohol, polyethylene terephthalate, polyacrylamide, polyacrylate, polyhydroxyethyl methacrylate, aromatic polyester, polysiloxane, polyurethane, polyethylene oxide, linear aliphatic polyester, polyamino acid or polyvinylpyrrolidone.

2. The sustained-release embolic microsphere of claim 1, wherein: the antibiotic is at least one of kanamycin, amikacin, capreomycin, levofloxacin and ciprofloxacin.

3. The sustained-release embolic microsphere of claim 1, wherein: the derivative of the antibiotic is at least one of kanamycin hydrochloride, kanamycin sulfate, amikacin sulfate, capreomycin sulfate, levofloxacin hydrochloride, levofloxacin lactate, levofloxacin mesylate, ciprofloxacin hydrochloride and ciprofloxacin lactate.

4. The sustained-release embolic microsphere of claim 1, wherein: the grain diameter is 10-1000 μm.

5. A slow release embolic microsphere as claimed in any one of claims 1 to 4, wherein: the organic material is water-soluble, and the preparation method comprises the following steps:

(1) preparing the antibiotic or the derivative thereof into an aqueous solution, and mixing the aqueous solution with the organic material to prepare a water phase;

(2) adding a surfactant into the liquid paraffin, and uniformly stirring to prepare an oil phase;

(3) adding the water phase into the oil phase, fully mixing, and carrying out emulsification or crosslinking reaction;

(4) and (4) centrifuging, washing and vacuum freeze-drying the material obtained in the step (3) to obtain the sustained-release embolism microsphere.

6. The sustained-release embolic microsphere of claim 5, wherein: the surfactant is at least one of sorbitan monooleate, propylene glycol monolaurate and propylene glycol fatty acid ester.

7. The sustained-release embolic microsphere of claim 5, wherein: the sorbitan monooleate is Span-80 or Arlacel-80, the propylene glycol monolaurate is Atlas G-917 or Atlas G-3851, and the propylene glycol fatty acid ester is Emcol PL-50.

8. A slow release embolic microsphere as claimed in any one of claims 1 to 4, wherein: the organic material is insoluble in water and is prepared by a method comprising:

(1) preparing the antibiotic or the derivative thereof into an aqueous solution;

(2) adding the aqueous solution into an organic phase containing the organic material, and performing vortex emulsification to form a water-in-oil emulsion;

(3) adding the water-in-oil emulsion into a water-soluble dispersant, and further emulsifying to form a water-in-oil-in-water emulsion;

(4) and (3) placing the water-in-oil-in-water emulsion in ice bath for ultrasonic treatment, stirring for 10-15h, and then sequentially centrifuging, washing and vacuum freeze-drying to obtain the slow-release embolism microsphere.

Technical Field

The invention belongs to the technical field of interventional medical treatment, and particularly relates to a sustained-release embolism microsphere for pulmonary tuberculosis hemoptysis.

Background

Hemoptysis is a bleeding of the respiratory system, mainly caused by diseases of the trachea, bronchi and lung tissues. Among the most common causes of hemoptysis are infectious lung diseases, a class of which includes tuberculosis (40%), bronchiectasis (30%), necrotizing pneumonia (10%), lung abscesses (5%) and fungal infections (5%). Whereas lung cancer and arteriovenous malformations account for only 10% of all cases.

The pulmonary tuberculosis hemoptysis has two main reasons, one is that cheese necrosis occurs when the pulmonary tuberculosis progresses, tissues collapse, and pulmonary vessels are corroded and damaged; the other is that the artery wall in the cavity wall of the cavity-type pulmonary tuberculosis loses the support of normal tissues and gradually bulges to form aneurysm, elastic fibers of the wall of the aneurysm are damaged, the brittleness is increased, and sudden change of pressure in blood vessels or rupture of necrotic blood vessels in the cavity wall can be caused under the influence of external factors such as severe cough or excessive chest expansion and the like, so fatal massive hemorrhage is caused.

Bronchial Artery Embolization (BAE) has the advantages of being minimally invasive, safe, fast in hemostatic effect and the like, and becomes a preferred method for clinically treating hemoptysis. The application of the anti-tuberculosis medicine suitable for BAE can relieve and inhibit the change of the focus lung structure and effectively avoid the relapse of hemoptysis.

Disclosure of Invention

The invention aims to provide a sustained-release embolism microsphere for pulmonary tuberculosis hemoptysis.

The technical scheme of the invention is as follows:

a sustained-release embolic microsphere for hemoptysis due to pulmonary tuberculosis is prepared from degradable or non-degradable organic material loaded with antibiotic or its derivative for resisting tubercle bacillus, wherein

The organic material is chitin, Chitosan (Chitosan), carboxymethyl Chitosan, sodium alginate, gelatin, collagen, Hyaluronic Acid (HA), polypeptide, silk fibroin, carboxymethyl starch, starch acetate, Polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid-polyglycolic acid copolymer (PLGA), polycaprolactone triol, polycaprolactone diol, poly (ethylene glycol) -block-poly (epsilon-caprolactone) methyl ether, polyvinyl alcohol (PVA), polyethylene terephthalate, Polyacrylamide (PAM), polyacrylate, polyhydroxyethyl methacrylate, aromatic polyester, polysiloxane, polyurethane, polyethylene oxide, linear aliphatic polyester, polyamino acid or polyvinylpyrrolidone (PVP).

In a preferred embodiment of the present invention, the antibiotic is at least one of kanamycin, amikacin, capreomycin, levofloxacin and ciprofloxacin.

In a preferred embodiment of the present invention, the derivative of the antibiotic is at least one of kanamycin hydrochloride, kanamycin sulfate, amikacin sulfate, capreomycin sulfate, levofloxacin hydrochloride, levofloxacin lactate, levofloxacin mesylate, ciprofloxacin hydrochloride, and ciprofloxacin lactate.

In a preferred embodiment of the invention, the particle size is from 10 to 1000. mu.m.

In a preferred embodiment of the present invention, the organic material is water-soluble, and the preparation method thereof comprises:

(1) preparing the antibiotic or the derivative thereof into an aqueous solution, and mixing the aqueous solution with the organic material to prepare a water phase;

(2) adding a surfactant into the liquid paraffin, and uniformly stirring to prepare an oil phase;

(3) adding the water phase into the oil phase, fully mixing, and carrying out emulsification or crosslinking reaction;

(4) and (4) centrifuging, washing and vacuum freeze-drying the material obtained in the step (3) to obtain the sustained-release embolism microsphere.

Further preferably, the surfactant is at least one of sorbitan monooleate, propylene glycol monolaurate and propylene glycol fatty acid ester.

Still further preferably, the sorbitan monooleate is Span-80 or Arlacel-80, the propylene glycol monolaurate is Atlas G-917 or Atlas G-3851, and the propylene glycol fatty acid ester is Emcol PL-50.

In a preferred embodiment of the present invention, the organic material is insoluble in water and is prepared by a method comprising:

(1) preparing the antibiotic or the derivative thereof into an aqueous solution;

(2) adding the aqueous solution into an organic phase containing the organic material, and performing vortex emulsification to form a water-in-oil emulsion;

(3) adding the water-in-oil emulsion into a water-soluble dispersant, and further emulsifying to form a water-in-oil-in-water emulsion;

(4) and (3) placing the water-in-oil-in-water emulsion in ice bath for ultrasonic treatment, stirring for 10-15h, and then sequentially centrifuging, washing and vacuum freeze-drying to obtain the slow-release embolism microsphere.

The invention has the beneficial effects that:

1. the invention can slowly release antituberculosis drugs while stopping bleeding by embolism, and acts on focus to relieve and inhibit the change of focus lung structure, thereby effectively avoiding the recurrence of hemoptysis.

2. The slow release of the antituberculosis drug can greatly improve the drug concentration of the focus part, relatively reduce the concentration of the drug in the circulatory system and reduce the side effect of the drug.

3. The combination of the medicine and the microspheres in the invention is convenient for doctors to operate and brings convenience to patients.

Drawings

FIG. 1 is a scanning electron microscope image of ciprofloxacin hydrochloride chitosan sustained-release embolization microspheres prepared in example 2 of the present invention.

FIG. 2 is a scanning electron microscope image of the ciprofloxacin hydrochloride polyvinyl alcohol sustained-release embolism microsphere prepared in example 3 of the present invention.

FIG. 3 is a scanning electron microscope image of the ciprofloxacin hydrochloride polycaprolactone sustained-release embolism microsphere prepared in example 4 of the present invention.

FIG. 4 is a scanning electron microscope image of the ciprofloxacin hydrochloride PLGA sustained-release embolization microsphere prepared in example 5 of the present invention.

FIG. 5 is a graph showing the results of in vitro drug release experiments of ciprofloxacin hydrochloride chitosan sustained-release embolic microspheres prepared in example 2 of the present invention.

FIG. 6 is a graph showing the in vitro release experiment results of the ciprofloxacin hydrochloride polyvinyl alcohol sustained release embolization microsphere prepared in example 3 of the present invention.

FIG. 7 is a diagram showing the results of in vitro drug release experiments of ciprofloxacin hydrochloride polycaprolactone sustained-release embolization microspheres prepared in example 4 of the present invention.

FIG. 8 is a graph showing the results of in vitro drug release experiments of ciprofloxacin hydrochloride PLGA sustained release embolization microspheres prepared in example 5 of the present invention.

Detailed Description

The technical solution of the present invention will be further illustrated and described below with reference to the accompanying drawings by means of specific embodiments.

Example 1

A sustained release embolism microsphere for pulmonary tuberculosis hemoptysis has particle diameter of 10-1000 μm. The material is degradable or non-degradable organic material, and antibiotic or its derivative for resisting tubercle bacillus is loaded in the material, wherein

The organic material is chitin, Chitosan (Chitosan), carboxymethyl Chitosan, sodium alginate, gelatin, collagen, Hyaluronic Acid (HA), polypeptide, silk fibroin, carboxymethyl starch, starch acetate, Polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid-polyglycolic acid copolymer (PLGA), polycaprolactone triol, polycaprolactone diol, poly (ethylene glycol) -block-poly (epsilon-caprolactone) methyl ether, polyvinyl alcohol (PVA), polyethylene terephthalate, Polyacrylamide (PAM), polyacrylate, polyhydroxyethyl methacrylate, aromatic polyester, polysiloxane, polyurethane, polyethylene oxide, linear aliphatic polyester, polyamino acid or polyvinylpyrrolidone (PVP).

The antibiotic is at least one of kanamycin, amikacin, capreomycin, levofloxacin and ciprofloxacin. The derivative of the antibiotic is at least one of kanamycin hydrochloride, kanamycin sulfate, amikacin sulfate, capreomycin sulfate, levofloxacin hydrochloride, levofloxacin lactate, levofloxacin mesylate, ciprofloxacin hydrochloride and ciprofloxacin lactate.

When the organic material is water-soluble, the preparation method thereof comprises:

(1) preparing the antibiotic or the derivative thereof into an aqueous solution, and mixing the aqueous solution with the organic material to prepare a water phase;

(2) adding a surfactant into the liquid paraffin, and uniformly stirring to prepare an oil phase, wherein the surfactant is at least one of sorbitan monooleate (Span-80/Arlacel-80), propylene glycol monolaurate (Atlas G-917/Atlas G-3851) and propylene glycol fatty acid ester (Emcol PL-50);

(3) adding the water phase into the oil phase, fully mixing, and carrying out emulsification or crosslinking reaction;

(4) and (4) centrifuging, washing and vacuum freeze-drying the material obtained in the step (3) to obtain the sustained-release embolism microsphere.

When the organic material is not soluble in water, the preparation method thereof comprises:

(1) preparing the antibiotic or the derivative thereof into an aqueous solution;

(2) adding the aqueous solution into an organic phase containing the organic material, and performing vortex emulsification to form a water-in-oil emulsion;

(3) adding the water-in-oil emulsion into a water-soluble dispersant, and further emulsifying to form a water-in-oil-in-water emulsion;

(4) and (3) placing the water-in-oil-in-water emulsion in ice bath for ultrasonic treatment, stirring for 10-15h, and then sequentially centrifuging, washing and vacuum freeze-drying to obtain the slow-release embolism microsphere.

Example 2 preparation of ciprofloxacin hydrochloride Chitosan sustained-release embolization microspheres

(1) Preparation of microspheres

Dissolving ciprofloxacin hydrochloride in water to prepare a medicinal solution. Dissolving the prepared 10% chitosan solution in 50-60 deg.C water bath, adding the above medicinal solution, and mixing in vortex mixer to obtain water phase. Adding a proper amount of Span-80 into liquid paraffin to prepare an oil phase, placing the oil phase in a three-necked bottle in a constant-temperature water bath at 50 ℃, slowly and dropwise adding a water phase into the oil phase for emulsification under the condition that the stirring speed is 200-1000rpm, wherein the volume ratio of the water phase to the oil phase is 1: 4-1: 8. When the emulsion drops are made into spheres with proper size through microscopic examination, namely emulsifying to form stable W/O type emulsion, quickly cooling to below 5 ℃, respectively adding formaldehyde or 50% glutaraldehyde for curing for 1-2h, centrifuging the obtained material at 3000rpm, washing with isopropanol and acetone for 3 times, filtering, and freeze-drying in vacuum to finally obtain the ciprofloxacin hydrochloride chitosan sustained-release embolism microsphere shown in figure 1.

(2) Encapsulation efficiency and drug load measurements

Chromatographic conditions are as follows: c₁₈Analytical column 4.6mm × 2.5mm, 5 μm;

mobile phase 0.025mol/L phosphoric acid solution-acetonitrile 87: 13

Adjusting pH value to 3.0 +/-0.1 by triethylamine

Ultraviolet detector with detection wavelength of 278nm

In the preparation process of the microspheres, the waste liquid in each step is collected, the ciprofloxacin hydrochloride content in the waste liquid is detected by high performance liquid chromatography, and the encapsulation rate and the drug-loading rate are calculated according to the following formula:

(3) in vitro drug release assay

Weighing a proper amount of ciprofloxacin hydrochloride chitosan sustained-release embolism microspheres, adding PBS (20mmol/L, pH7.4) for wetting, then placing into a 50mL conical flask, adding 30mL of PBS containing 1 per thousand sodium azide, then placing the conical flask into a constant-temperature water bath shaking table, setting the temperature at 37 ℃, and rotating at 80 rpm. Samples were taken at 1, 2, 3, 5, 7, 14, 21, 28d after placement, 5mL each time, supplemented with 5mL PBS. Centrifuging the sample, taking the supernatant to detect the ciprofloxacin hydrochloride content, and calculating the cumulative release according to the following formula:

as a result: the average encapsulation rate of the ciprofloxacin hydrochloride chitosan sustained-release embolism microsphere prepared by the embodiment reaches 92.19%, and the average drug-loading rate is 9.07%; according to the in vitro release law, as can be seen from the cumulative release curve shown in fig. 5, the release rate is faster in week 1, and the release rate gradually slows down from week 2, with the curve also tending to be slightly gentle. The cumulative release of drug from the microspheres exceeded 40% over a 4 week period. Can meet the characteristics of taking interventional embolism as the main part and taking drug therapy as the auxiliary part in the clinical treatment of pulmonary tuberculosis hemoptysis.

Example 3 preparation of Cyclopropylxacin hydrochloride polyvinyl alcohol sustained-release embolism microsphere

(1) Preparation of microspheres

Under the condition of stirring, adding 2g of surfactant Span-80 into 40mL of liquid paraffin to form a continuous phase oil phase; after stirring uniformly, 10mL of a mixed solution of polyvinyl alcohol and ciprofloxacin hydrochloride was added to the continuous oil phase, and after thorough mixing, 1g of Sodium Trimetaphosphate (STMP) was added as a crosslinking agent, and 1mL of NaOH was immediately added as a catalyst. The rotation speed is set to be 400rpm, the temperature is set to be 50 ℃, and the crosslinking reaction time is set to be 16 h. After the crosslinking reaction was completed, the mixture was allowed to stand for 30 min. Adding a small amount of anhydrous ethanol, centrifuging in a centrifuge, taking out supernatant, repeatedly washing precipitate with anhydrous ethanol, isopropanol and pure water, and vacuum freeze drying to obtain ciprofloxacin hydrochloride polyvinyl alcohol sustained release embolism microsphere shown in figure 2.

(2) Encapsulation efficiency and drug load measurements

Chromatographic conditions are as follows: c₁₈Analytical column 4.6mm × 2.5mm, 5 μm;

mobile phase 0.025mol/L phosphoric acid solution-acetonitrile 87: 13

Adjusting pH value to 3.0 +/-0.1 by triethylamine

Ultraviolet detector with detection wavelength of 278nm

In the preparation process of the microspheres, the waste liquid in each step is collected, the ciprofloxacin hydrochloride content in the waste liquid is detected by high performance liquid chromatography, and the encapsulation rate and the drug-loading rate are calculated according to the following formula:

(3) in vitro drug release assay

Weighing a proper amount of the ciprofloxacin hydrochloride polyvinyl alcohol sustained-release embolism microsphere prepared in the embodiment, adding PBS (20mmol/L, pH7.4) for wetting, then placing the mixture into a 50mL conical flask, adding 30mL of PBS containing 1 per thousand of sodium azide, then placing the conical flask into a constant-temperature water bath shaking table, setting the temperature at 37 ℃ and rotating the speed at 80 rpm. Samples were taken at 1, 2, 3, 5, 7, 14, 21, 28d after placement, 5mL each time, supplemented with 5mL PBS. Centrifuging the sample, taking the supernatant to detect the ciprofloxacin hydrochloride content, and calculating the cumulative release according to the following formula:

as a result: the average entrapment rate of the ciprofloxacin hydrochloride polyvinyl alcohol sustained-release embolism microsphere prepared by the embodiment reaches 87.6%, and the average drug-loading rate is 8.42%; according to the in vitro release law, as can be seen from the cumulative release curve shown in fig. 6, the release rate is faster in week 1, and the release rate gradually slows down from week 2, with the curve also tending to be slightly gentle. The cumulative release of drug from the microspheres exceeded 40% over a 4 week period. Can meet the characteristics of taking interventional embolism as the main part and taking drug therapy as the auxiliary part in the clinical treatment of pulmonary tuberculosis hemoptysis.

Example 4 preparation of ciprofloxacin hydrochloride polycaprolactone sustained-release embolism microsphere

(1) Preparation of microspheres

Dissolving polycaprolactone in dichloromethane under a closed condition, adding Span-80, and uniformly mixing to obtain an oil phase; adding ciprofloxacin hydrochloride solution serving as an inner water phase into the oil phase, and performing ultrasonic treatment for 3min to form primary emulsion; adding PVA water solution into the primary emulsion, and performing ultrasonic treatment again to form W/O/W type composite emulsion; stirring the obtained composite emulsion for 3 hours at room temperature under an open condition, and volatilizing dichloromethane; washing with distilled water for 2 times, and lyophilizing to obtain ciprofloxacin hydrochloride polycaprolactone sustained-release embolism microsphere shown in figure 3.

(2) Encapsulation efficiency and drug load measurements

Chromatographic conditions are as follows: c₁₈Analytical column 4.6mm × 2.5mm, 5 μm;

mobile phase 0.025mol/L phosphoric acid solution-acetonitrile 87: 13

Adjusting pH value to 3.0 +/-0.1 by triethylamine

Ultraviolet detector with detection wavelength of 278nm

In the preparation process of the microspheres, the waste liquid in each step is collected, the ciprofloxacin hydrochloride content in the waste liquid is detected by high performance liquid chromatography, and the encapsulation rate and the drug-loading rate are calculated according to the following formula:

(3) in vitro drug release assay

Weighing a proper amount of ciprofloxacin hydrochloride polycaprolactone sustained-release embolism microsphere prepared in the embodiment, adding PBS (20mmol/L, pH7.4) for wetting, then placing into a 50mL conical flask, adding 30mL of PBS containing 1 per thousand of sodium azide, then placing the conical flask into a constant-temperature water bath shaking table, setting the temperature at 37 ℃, and rotating speed at 80 rpm. Samples were taken at 1, 2, 3, 5, 7, 14, 21, 28d after placement, 5mL each time, supplemented with 5mL PBS. Centrifuging the sample, taking the supernatant to detect the ciprofloxacin hydrochloride content, and calculating the cumulative release according to the following formula:

as a result: the average entrapment rate of the ciprofloxacin hydrochloride polycaprolactone sustained-release embolism microsphere prepared by the embodiment reaches 72.44%, and the average drug loading rate is 6.83%; according to the in vitro release law, as can be seen from the cumulative release curve shown in fig. 7, the release rate is faster in week 1, and the release rate gradually slows down from week 2, with the curve also tending to be slightly gentle. The cumulative release of drug from the microspheres exceeded 40% over a 4 week period. Can meet the characteristics of taking interventional embolism as the main part and taking drug therapy as the auxiliary part in the clinical treatment of pulmonary tuberculosis hemoptysis.

Example 5 preparation of ciprofloxacin hydrochloride PLGA sustained-release embolic microspheres

(1) Preparation of microspheres

Under a closed condition, dissolving PLGA in dichloromethane, adding Span-80, and uniformly mixing to obtain an oil phase; adding ciprofloxacin hydrochloride solution serving as an inner water phase into the oil phase, and performing ultrasonic treatment for 3min to form primary emulsion; adding PVA water solution into the primary emulsion, and performing ultrasonic treatment again to form W/O/W type composite emulsion; stirring the obtained composite emulsion for 3 hours at room temperature under an open condition, and volatilizing dichloromethane; washing with distilled water for 2 times, and lyophilizing to obtain ciprofloxacin hydrochloride PLGA sustained release embolism microsphere shown in figure 4.

(2) Encapsulation efficiency and drug load measurements

Chromatographic conditions are as follows: c₁₈Analytical column 4.6mm × 2.5mm, 5 μm;

mobile phase 0.025mol/L phosphoric acid solution-acetonitrile 87: 13

Adjusting pH value to 3.0 +/-0.1 by triethylamine

Ultraviolet detector with detection wavelength of 278nm

In the preparation process of the microspheres, the waste liquid in each step is collected, the ciprofloxacin hydrochloride content in the waste liquid is detected by high performance liquid chromatography, and the encapsulation rate and the drug-loading rate are calculated according to the following formula:

(3) in vitro drug release assay

Weighing a proper amount of ciprofloxacin hydrochloride PLGA sustained-release embolism microsphere prepared in the embodiment, adding PBS (20mmol/L, pH7.4) for wetting, then placing into a 50mL conical flask, adding 30mL of PBS containing 1 per thousand of sodium azide, then placing the conical flask into a constant-temperature water bath shaking table, setting the temperature at 37 ℃, and rotating at 80 rpm. Samples were taken at 1, 2, 3, 5, 7, 14, 21, 28d after placement, 5mL each time, supplemented with 5mL PBS. Centrifuging the sample, taking the supernatant to detect the ciprofloxacin hydrochloride content, and calculating the cumulative release according to the following formula:

as a result: the average entrapment rate of the ciprofloxacin hydrochloride PLGA sustained-release embolism microsphere prepared by the embodiment reaches 78.05%, and the average drug-loading rate is 7.1%; according to the in vitro release law, as can be seen from the cumulative release curve shown in fig. 8, the release rate is faster in week 1, and the release rate gradually slows down from week 2, with the curve also tending to be slightly gentle. The cumulative release of drug from the microspheres exceeded 40% over a 4 week period. Can meet the characteristics of taking interventional embolism as the main part and taking drug therapy as the auxiliary part in the clinical treatment of pulmonary tuberculosis hemoptysis.

The above description is only for the preferred embodiment of the present invention, and therefore should not be taken as limiting the scope of the invention, which is defined by the appended claims.